Efficacy and safety of paliperidone extended-release tablets in treatment of patients with schizophrenia:a randomized ziprasidone hydrochloride capsules controlled study

Objective:The study was designed to evaluate the efficacy and safety of paliperidone extended-release tablets comparing with ziprasidone hydrochloride capsules in outpatient with schizophrenia.Method:There were 48 schizophrenic patients in study group treated with paliperidone extended-release tablets and 51 schizophrenic patients in control group with ziprasidone hydrochloride capsules for the treatment of 6 weeks.They were assessed with positive and negative symptoms scales(PANSS),treatment emergent symptom scale(TESS) and personal and social performance(PSP) in the treatment period.Results:The scores of PANSS in the 2nd and 6th week of treatment were all significantly lower than those in basline(P0.05),the total and factors scores of PANSS in study group were all significantly lower than those in control group(P 0.05),and the scores of PSP in study group was significantly higher than in control group PSP(60.32±8.24) vs(53.38±6.90)(P0.001).The common adverse events were extrapyramidal symptoms,insomnia,constipation and prolactin increasing in paliperidone ER group.and QTc interval prolongation,insomnia,headache and nausea in ziprasidone hydrochloride group.Conclusion:Paliperidone extended-release tablet is more effective in improving positive symptoms,negative symptoms and social function of schizophrenic patients than ziprasidone hydrochloride capsule.